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Abstract
 
Germline mutations in 
 
Fas
 
 and 
 
Fasl
 
 induce nonmalignant T cell hyperplasia and systemic au-
toimmunity and also greatly increase the risk of B cell neoplasms. B lymphomas occurring in
 
Fasl
 
 mutant (
 
gld
 
) mice usually are immunoglobulin (Ig) isotype switched, secrete Ig, and are
plasmacytoid in appearance but lack 
 
Myc
 
 translocations characteristic of other plasma cell (PC)
neoplasms. Here, we explore the relationship between B cell autoreactivity and transformation
and use gene expression profiling to further classify 
 
gld
 
 plasmacytoid lymphomas (PLs) and to
identify genes of potential importance in transformation. We found that the majority of PLs
derive from antigen-experienced autoreactive B cells producing antinuclear antibody or rheu-
matoid factor and exhibit the skewed Ig V gene repertoire and Ig gene rearrangement patterns
associated with these specificities. Gene expression profiling revealed that both primary and
transplanted PLs share a transcriptional profile that places them at an early stage in PC differen-
tiation and distinguishes them from other B cell neoplasms. In addition, genes were identified
whose altered expression might be relevant in lymphomagenesis. Our findings provide a strong
case for targeted transformation of autoreactive B cells in 
 
gld
 
 mice and establish a valuable
model for understanding the relationship between systemic autoimmunity and B cell neoplasia.
Key words: autoimmunity • B cell lymphoma
 
Introduction
 
Mice and humans with germline (GL) mutations in 
 
Fas
 
 or
 
Fasl
 
 develop early onset, progressive autoimmune lympho-
proliferative syndromes, termed ALPS in humans, character-
ized by nonmalignant T cell hyperplasia, massive lymphade-
nopathy and splenomegaly, hypergammaglobulinemia, and
systemic autoimmunity. As the disease progresses, mice
mutant in 
 
Fas
 
 (l
 
pr
 
) or 
 
Fasl
 
 (
 
gld
 
) also accumulate memory-like
B cells and plasma cells (PCs), and produce high titers of IgG
antinuclear antibody (ANA; references 1 and 2). These anti-
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bodies include specificities for double-stranded DNA (ds-
DNA) and histones and, in large part, are encoded by a re-
stricted set of IgH and IgL genes with members of the V
 
H
 
J558 and 7183 families as a prominent feature (3). V
 
L 
 
gene
use by antibodies specific for DNA–histone complexes, al-
though also restricted, is more diverse than V
 
H 
 
use and in-
volves members of at least 10 V
 
  
 
gene groups (3). In spite of
this biased repertoire, the autoimmune responses to nuclear
antigen by 
 
lpr
 
/
 
gld
 
 and other autoimmune mice resemble
normal, secondary antibody responses to foreign antigen,
and affinity maturation of the autoimmune ANA responses
appears to be the result of antigen drive (4, 5). Thus, within
the B cell compartment of 
 
lpr
 
 and 
 
gld
 
 mice, there is evidence
for loss of tolerance to and chronic stimulation by DNA–
histone complexes.
GL mutations in 
 
Fas/Fasl
 
 also greatly increase the risk of
B cell neoplasia in humans and mice. B cell lymphomas in
autoimmune lymphoproliferative syndrome patients are pre-
dominantly  follicular and phenotypically diverse (6). In
mice, lymphomas develop between 6 and 12 mo of age,
and tumor incidence is strain related. By 1 yr of age, 
 
 
 
30%
of C3H-
 
gld
 
 and 60% of BALB-
 
gld
 
 mice have monoclonal
outgrowths of B cells in the spleen and LN that metastasize
to nonlymphoid organs (2). These tumors can be passaged
to purity in immunodeficient 
 
scid
 
 mice and are lethal for
their hosts (2). The 
 
scid
 
-passaged 
 
lpr
 
 and 
 
gld
 
 B cell lympho-
mas are predominantly plasmacytoid in morphology, are
 
 
 
dull
 
  
 
CD23
 
  
 
CD21
 
  
 
Mac-1
 
 
 
, have undergone Ig isotype
switching, and spontaneously secrete Ig (2), suggesting that
they derive from antigen-experienced, possibly germinal
center (GC)-selected B cells.
Lymphomagenesis is a multistep process involving both
genetic and environmental factors. There is mounting evi-
dence that chronic antigen stimulation might be an impor-
tant environmental factor. In support of this, there are re-
ports that within the Ig V
 
H 
 
and V
 
L 
 
genes of many B cell
tumors and clonal progeny of nontransformed cells there is
a counterselection for replacement mutations (R muta-
tions) in the framework regions (FWRs) of the B cell re-
ceptor (BCR) and generally higher ratios of R versus silent
mutations (S mutations) in the complementarity-determin-
ing regions (CDRs; references 7–11). The persistence of
these mutational patterns in the face of ongoing somatic
mutation suggests that there is strong selective pressure to
preserve the structural integrity of the BCR. Moreover,
analyses of intraclonal variation in human follicular lym-
phomas revealed genealogic relations between subclones,
indicative of antigen-driven clonal evolution (12, 13). Other
compelling evidence that chronic antigen stimulation might
be a factor in B cell lymphomagenesis comes from studies
of mucosal-associated lymphoid tissue (MALT) B cell lym-
phomas. These tumors are thought to derive from marginal
zone B cells and develop at sites of chronic inflammation
caused by autoimmune disease or infection (14–19). As ex-
amples, patients with Sjögren’s syndrome or Hashimoto’s
thyroiditis have an increased risk of developing MALT
lymphomas of the salivary and thyroid glands, respectively
(15–17). Notably, in both patient populations, MALT lym-
phomas have been reported that produce rheumatoid factor
(RF) and exhibit nonrandom use of IgV
 
H 
 
and V
 
L 
 
genes,
suggesting that autoreactive B cells chronically stimulated
by nominal self-antigen might be selectively targeted for
transformation (14, 17, 18). Of interest, C57BL/6-
 
lpr
 
 mice
deficient in all T lineage cells also develop B lymphomas
that produce RF (20).
The goals of this study were twofold. First, we sought to
determine whether B cell transformation in 
 
gld
 
 mice is a
random event or is skewed toward chronically stimulated,
autoreactive B cells. Second, we undertook gene expres-
sion profiling using oligonucleotide-based microarrays to
determine whether the 
 
gld
 
 plasmacytoid tumors exhibit a
transcriptional profile that might be useful for diagnosis and
relevant to pathogenesis.
 
Materials and Methods
 
Mice.
 
BALB/c-
 
gld/gld
 
 (BALB-
 
gld
 
) mice were bred and main-
tained in the Holland Laboratory vivarium. C.B-17-
 
scid/scid
 
 (
 
scid
 
)
mice were purchased from Taconic. SJL/J mice with a null muta-
tion of the 
 
 
 
-2 microglobulin gene [SJL/J-
 
 
 
2M
 
 
 
/
 
 
 
/Dcr (N11)]
were bred and raised at The Jackson Laboratory. Animal research
protocols were approved by the American Red Cross Institu-
tional and Animal Care Use Committee.
 
Tumors.
 
Early passage number (P1 or P2) plasmacytoid lym-
phomas (PLs), including 13 BALB-
 
gld 
 
and 6 C3H-
 
gld
 
, were trans-
planted i.p. into 4–6-wk-old 
 
scid
 
 mice. Sera, spleens, and mesen-
teric LNs were harvested from tumor-bearing mice. Single cell
suspensions were made for FACS analysis and isolation of DNA
and RNA. Southern hybridization analysis for IgH and IgL gene
rearrangements was used to establish clonality (2). The proportion
of tumor cells in spleen and LN samples was determined by FACS
analysis (BD Biosciences). The majority of the tumor cell prepara-
tions contained 
 
 
 
90% CD19
 
  
 
B cells with high forward and side
scatter. Primary tumor cells were obtained from four mice with
advanced tumors and were enriched by MACS sorting (Miltenyi
Biotec) of CD19
 
  
 
cells. These cells were predominantly CD23
 
 
 
CD21
 
  
 
Mac-1
 
  
 
with high forward and side scatter. Non-
 
gld
 
 lym-
phomas used in array analyses were mostly from NFS.V
 
  
 
congenic
mice (21), but included plasmacytoma (PCT) cell lines provided
by M. Potter (National Cancer Institute, Bethesda, MD) and pri-
mary lymphomas of SJL/J-
 
 
 
2M
 
 
 
/
 
  
 
mice.
 
Cultures.
 
Sorted CD19
 
  
 
CD23
 
  
 
tumor cells were cultured at
10
 
7
 
/ml in supplemented RPMI medium for 48 h in the presence
or absence of 25 
 
 
 
g/ml LPS (Sigma-Aldrich).
 
ELISA for Ig Isotypes, ANA, Single-Stranded DNA (ssDNA),
and RF.
 
Ig isotypes and ANA, anti-ssDNA, and RF titers in
sera from tumor-bearing mice and tumor tissue culture superna-
tants were determined using a mouse Ig isotyping ELISA kit (BD
Biosciences) and ANA, ssDNA, and RF ELISA kits (Alpha Diag-
nostic International). Antibodies to dsDNA were detected by
ELISA as described previously (2). Nuclear staining was detected
using a kit (Antibodies Inc.).
 
Cloning and Characterization of Ig Genes.
 
Total RNA was iso-
lated from tumor cells using TRIzol reagent (Invitrogen). First-
strand cDNA was generated using oligo (dT) or random primers
and SuperScript (Invitrogen). PCR amplification of tumor V
 
H 
 
and
V
 
L 
 
genes was performed using a set of degenerate primers and con-
ditions listed in Table S1 (see Online Supplemental Material sec-
tion below). Selected PCR products were cloned using a TOPO 
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TA cloning kit (Invitrogen). Multiple independent plasmid isolates
for V
 
H 
 
and V
 
L 
 
were sequenced for each tumor. Ig gene sequences
were searched for their closest GL sequence match against a DNA
and protein database (http://www.ncbi.nlm.nih.gov/BLAST), a
database for Ig genes (http://www.ncbi.nlm.nih.gov/igblast), and
the Celera database. The probability that an excess of R mutations
in CDR1 and CDR2 regions or a scarcity of R mutations in
FWRs occurred by chance was calculated using a multinomial dis-
tribution model and a published program (http://www.stat.stanford.
edu/immunoglobin; reference 22).
 
Oligonucleotide Microarrays.
 
Microarray chips, printed by the
Microarray Research Facility at NIAID (http://madb.niaid.nih.gov),
comprised 
 
 
 
6,700 mouse gene targets represented by 70-mer
oligonucleotides purchased from Compugen. Total tumor cell
RNA was extracted by the TRIzol protocol and further purified
using the RNeasy column-based protocol (QIAGEN). A refer-
ence sample was created by extracting total RNA from 10 well-
characterized hematopoietic cell lines and making a pool com-
prising equal amounts of RNA from each line (Table S2; see
Online Supplemental Material section below). The labeling of
cDNA, chip hybridization, and chip scanning were performed as
described previously (23). The microarray data accession number
is GSE1908.
 
Microarray Data Analysis.
 
The microarray dataset was orga-
nized and analyzed using SAS software (SAS Institute). From a to-
tal of 6,800 genes, 5,770 genes had 
 
 
 
30% of missing values across
all 134 samples. For these genes, the missing values were replaced
with the overall mean of each individual gene, and this no-miss-
ing-value dataset was used in the subsequent principal component
analysis (PCA). Student’s 
 
t 
 
test and the nonparametric Kruskall-
Wallis test were used to compare the expression levels of genes
among different lymphoma groups. Hierarchical clustering (aver-
age linkage method) of selected significant genes against lymphoma
samples was performed using a program available in the NIAID
microarray database application (http://madb.niaid.nih.gov).
 
Quantitative PCR.
 
Primers and conditions for quantitative
PCR are given in Table S3 (see Online Supplemental Material
section below).
 
Online Supplemental Material.
 
The supplemental materials in-
clude the following: (a) primers and conditions for PCR amplifi-
cation of V
 
H 
 
and V
 
L 
 
genes (Table S1); (b) cell lines used to gen-
erate the standard for microarrays (Table S2); (c) primers for
quantitative PCR (Table S3); (d) translated amino acid sequences
of V
 
H 
 
and V
 
L 
 
for 
 
gld
 
 tumors (Fig. S1); (e) V
 
H
 
-D
 
H
 
-J
 
H 
 
rearrangement
of tumor V
 
H 
 
CDR3 regions (Fig. S2); (f) hierarchical clustering of
415 genes that discriminate 
 
gld
 
 PL from other mouse lymphomas
(Fig. S3); (g) the same data as shown in Fig. S3 with all genes
identified (Fig. S4); (h) hierarchical clustering of gene expression
data for 99 genes that distinguish gld PLs from other PC neoplasms
(Fig. S5); and (i) the same data as shown in Fig. S5 with all genes
identified (Fig. S6). Tables S1–S3 and Figs. S1–S6 are available at
http://www.jem.org/cgi/content/full/jem.20041575/DC1.
Results
Phenotype and Antibody Specificity of gld PLs. PLs, 12 from
BALB-gld and 6 from C3H-gld mice, were analyzed for sur-
Table I. Isotypes and Nuclear Antigen Reactivity of Antibodies Secreted by gld Tumors
Tumor Isotype ssDNA dsDNA ANA Nuclear staining RF CL PPC
BALB-gld
208 IgG1, Ig   a        b   
329 IgM, Ig              
421 IgM, Ig              
424 Multiplec, Ig             
425 IgG2a, Ig  ( )d    ( )     
426 IgA, Ig         ( )   
531 IgM, Ig              
593 IgG2a, Ig             
600 IgG2a, IgG3, Ig             
2685 IgG2a, Ig             
3294 IgM, Ig              
8850 ND    ND    ND ND
C3H-gld
205 IgG2a, Ig        ( )   
217 IgG3, Ig  ( )           
221 IgA, Ig              
223 IgG3, Ig              
355 IgG2a, Ig             
a , no detectable reactivity.
b , strongly reactive.
cMultiple, more than two Ig isotypes secreted.
d( ), weakly reactive.Selective Transformation of Autoreactive gld B Cells 1470
face phenotype, Ig isotype, and Ig specificity. The panel in-
cluded 14 previously characterized tumors (2) and 4 new
BALB-gld tumors (593, 600, 2685, and 3294). One partially
characterized BALB-gld tumor, 8850, also was included.
Early scid passages (P1 or P2) of tumors were used to maxi-
mize the closeness of genotype and phenotype to the pri-
mary tumors. The majority of tumors was CD19  Mac-1dull
Ig dull CD23  CD21  CD5dull or CD5 , a phenotype re-
markably similar to that of the nontransformed B cells that
selectively accumulate in old lpr and gld mice (2, 24, 25).
The Ig isotype produced by the tumors was determined by
testing sera from tumor-bearing scid mice and supernatants
from cultures of sorted tumor cells. All 16 sera tested con-
tained significantly elevated levels of Ig, and isotype switch-
ing had occurred in 11 (Table I). One tumor, 424, produced
polyreactive antibodies of different isotypes that were reac-
tive in ELISA assays for dsDNA, phosphorylcholine (PPC),
and cardiolipin (CL). Tumor 600 consistently secreted both
IgG2a and IgG3 in several scid passages (Table I). Ig was not
detected in sera from control scid mice (not depicted). The
sera also were assayed for ANA, RF, and antibodies to
dsDNA, ssDNA, PPC, and CL. 9 of 16 (56%) sera tested
positive for ANA by ELISA and for nuclear staining de-
tected by immunohistochemistry (Table I). Within this
group, Ig from tumor 426 also reacted strongly with ssDNA
and was weakly positive for RF. Only antibodies from 221,
424, and 2685 reacted with dsDNA. antibodies from two
ANA  tumors, 217 and 421, also reacted with ssDNA. Al-
though negative for ANA activity by ELISA, antibodies
from 425 showed weak reactivity with nuclei, weak reac-
tivity with ssDNA, and had high titers of RF. Tumor 8850
produced high titers of RF and anti-ssDNA antibodies, and
tumors 205 and 208 produced RF only. Cross-reactivity be-
tween RF and ssDNA has been reported previously (26).
With the exception of 424, no tumors produced antibodies
reactive with PPC or CL. In all, 15 of 17 Ig-secreting tu-
mors produced RF and/or antibodies reactive with nuclear
antigens. 4 of 17 tumors produced antibodies that appeared
to be polyreactive. Results obtained with tumor culture su-
pernatants conformed to those from sera of scid mice bearing
the same tumor (not depicted).
Selected Use of the VH J558 Family and Individual Subfamily
Members in gld Tumors. To determine the Ig gene reper-
toire of the tumors, we sequenced the VH and VL genes us-
Table II. Use of V, D, and J Segments of Tumor IgVH and IgVL Sequences
Heavy chain variable region Light chain variable region
Tumor DNAa AAa GLb VH
c DH
d JH DNAa AAa GLb VL
e JL
BALB-gld
208 99.3 97.8 VGK1A VH9 P2.4/6, P2.7/9 JH4 99.6 98.9 21-7 v 21 Jk2
329 96.4 96.7 J558.52 J558 P2.12 JH4 99.6 100 cy9 v 9/10 Jk2
421 96.3 94.6 J558.17 J558 D16.1, P2.9 JH4 97.8 95.7 8-27 v 8J k5
424 97.3 94.9 J558.35 J558 P2.5/7 JH1 99.2 97.6 ai4 v 4/5 Jk5
425 95.7 89.1 J558.32 J558 P2.5/7, P2.13 JH2 98.5 95.7 cr1 v 1J k1
426 96.8 91.5 V-BK 7183 P2.4/6, P2.10 JH2 98.9 98.9 12-44 v 12/13 Jk5
531 98.2 95.7 J558.52 J558 D16.1, D16.2 JH2 97.3 94.3 19-13 v 19/28 Jk2
540 91.3 85.9 J558.2 J558 D16.2 JH2 100 100 21-2 v 21 Jk4
593 98.3 96.9 J558.52 J558 P2.4/6 JH4 98.9 96.6 ba9 v 9/10 Jk1
600 97.8 96.7 J558.22 J558 P2.9, P2.12 JH4 99.2 97.6 aq4 v 4/5 Jk5
2685 99.6 98.9 J558.18 J558 P2.4/6 JH4 97.3 95.4 21-7 v 21 Jk2
3294 98.9 96.7 VOx-1 Q52 D16.2 JH4 97.5 94.7 bd2 v 2J k1
C3H-gld
142 90.5 81.0 V130 J558 P2.x JH3 97.4 94.5 VL1 VL1 J 1
205 88.7 87.6 J558.18 J558 P2.9 JH4 92.3 88.5 19-13 v 19/28 Jk4
217 97.1 94.4 J558.47 J558 P2.9 JH2 98.6 96.8 gj38c v 38c Jk2
221 96.8 95.8 VH7183.3b 7183 P2.5 JH2 99.6 98.9 23-39 v 23 Jk4
223 94.4 91.7 J558.40 J558 P2.12 JH4 99.2 97.7 at4 v 4/5 Jk5
355 99.3 97.8 VH7183.1j 7183 P2.12 JH3 99.3 99.0 12-44 v 12/13 Jk1
aPercent homology between tumor DNA and amino acid (AA) sequences and GL.
bClosest matched GL genes.
cVH family.
dDH segment. DH family abbreviations: P, DSP; D, DFL; T, DST.
eVL family.Zhang et al. 1471
ing multiple plasmid isolates from each of the 18 tumors in
the panel. As shown in Table II, 13 of the tumor VH gene
sequences (72.2%) aligned with a member of the J558 (VH1)
family, 3 (16.7%) belonged to the 7183 (VH5) family, and 1
each to the Q52 and VGAM3.8 (VH9) families. The VH
J558 family GL gene assignments were made on the basis of
homology with BALB/c J558 GL sequences (27) and C3H
GL sequences in the Celera database. The overall DNA and
predicted amino acid sequence homology between each tu-
mor DNA and the assigned GL VH gene was  94% in the
majority of cases. For the five tumors with  95% homol-
ogy, the degree of homology exceeded 80%, the considered
lower limit of homology required for accurate assignment
to a particular VH family (28). Although we are confident
that the family assignments are correct, the subfamily assign-
ments for tumors 142, 205, and 540 may need revision as
more GL J558 sequences become available. The frequency
of J558 family use among the BALB-gld tumors (75%, 9 of
12 sequences) differed significantly ( 2, P   0.05) from that
reported for normal BALB/c B cells (51%, 30 of 59 se-
quences; reference 29). A similar trend was observed in the
C3H-gld tumors, where 66.7% (four of six) used J558 genes.
Analysis of J558 subfamily gene use revealed some bias in
the BALB-gld tumors, particularly those with nuclear reac-
tivity. Three ANA-producing tumors, 329, 531, and 593,
were highly homologous ( 96% similarity) with J558.52, a
gene found only once in 128 randomly selected J558 cDNA
from normal BALB/c B cells (Table II; reference 27). The
alignment of the predicted VH amino acid sequences for
these tumors with the GL J558.52 sequence from FWR1 to
FWR3 is shown in Fig. S1 A, available at http://www.jem.
org/cgi/content/full/jem.20041575/DC1. Another J558 gene,
J558.18, was used by two tumors, 205 and 2685. Consistent
with these findings, anti-DNA antibodies derived from
MRL-lpr and (NZBxNZW)F1 mice frequently are encoded
by  J558 genes with a high degree of homology with
J558.52 and J558.18 (3, 5, 30). Similarly, tumor 221, which
secretes antibodies reactive with nuclear antigen and ds-
DNA, used 7183.3b, a gene frequently used by anti-dsDNA
antibodies (Table II; references 5 and 30). Tumor 221 and
ANA-producing tumor 426, which also is encoded by a
7183 family member, retained the GL putative DNA-con-
tacting RN motif at positions 76 and 77 of FWR3 (Fig. S1
A; reference 3). In all cases, tumor cDNA Ig sequences
were verified by genomic sequencing.
Evidence for Nonrandom Use of DH and JH Genes in PLs.
Analysis of 18 tumor CDR3 DH sequences revealed evi-
dence of D–D fusions and significant skewing in DH family
use (Table II and Fig. S2). Fusion of two D segments, rare
in normal B cells, was observed in six tumors. Altogether,
15 of 18 tumors (83.3%) used a D segment from the DSP2
family, whereas 4 tumors used D genes from the DFL fam-
ily. In contrast, in a previous study, 50% to 55% of BALB/
c follicular B cells used DSP family members (29). Notably,
many tumor VH CDR3 sequences contained one or more
R and N residues, a frequent feature of ANA (3). In many
cases, the R and N residues were generated by N region
nucleotides (Fig. S2). One motif, [(W)LR(R)n], found re-
currently in anti-DNA antibodies (3, 5, 30), was present in
the VH CDR3 region of tumors 426, 593, 600, and 2685, a
finding consistent with the production of ANA and anti-
DNA antibodies by these tumors (Table I).
Biased usage of JH segments was also observed in the tu-
mors, particularly in the BALB-gld group (Table II and Fig.
S2). Overall, the JH distribution was 5.6% JH1, 33.3% JH2,
11.1% JH3, and 50% JH4. By comparison, the JH family us-
age in normal BALB/c B2 cells was reported to be 9% JH1,
25% JH2, 32% JH3, and 34% JH4 (29). The tumor and B2
cell JH distributions differ significantly ( 2, P   0.0001).
The JH4 bias was even more prominent (57%) if only the
14 tumors with demonstrated autoreactivity were consid-
ered (Tables I and II).
Biased Use of VL Gene Families and J  Genes in PLs. In
normal B cells, the pattern of VL family usage generally cor-
responds to the estimated family size (31). Two exceptions
are the V 1 and V 4 families, which each account for  13%
of the expressed VL genes (31, 32). Analyses of PL VL se-
quences revealed a pattern different from that in normal B
cells (Table II). Although 10 V  families were represented
among the PLs, the following three families were over-
represented: V 4/5 (15.8%), V 21 (15.8%), and V 12/13
(10.5%). Although the sample size is small, preferential sub-
family use within these families also was observed. Tumors
355 and 426 used V 12-44, and tumors 208 and 2685 used
21-7 (Table II). Notably, both of these V  subfamilies are
represented frequently in anti-DNA antibodies (3, 5).
Similar to the VH genes, the VL genes also showed a trend
toward increased rearrangement to distal J genes (Table II).
JK1,  JK2, and JK5 each were used by 5 of 18 tumors
(27.8%), and JK4 was used by 3 of 18 tumors (16.7%). In
normal mouse B cells, the frequency of rearrangement to JK
loci is JK1   JK2   JK5    JK4, with  35% rearranging to
JK4 (13%) or JK5 (22%; reference 31). The frequency of JK4
or JK5 usage by the tumors (45%) differed significantly from
that of normal B cells ( 2, P   0.036).
Evidence for Antigen Selection in PLs. Patterns of DNA
mutation in Ig genes can provide valuable insights into the
maturational history of the tumor precursors and the im-
portance of BCR integrity, specificity, and affinity in tu-
morigenesis (7–11). To investigate the frequency and nature
of the mutations in tumor Ig genes, the distribution of R
versus S mutations in the FWR, CDR1, and CDR2 of V
genes was analyzed (22). Only data for VL genes is shown
because most of the mouse VL GL genes have been se-
quenced and the GL assignments for the tumors can be
made with greater confidence. In this analysis, a signifi-
cantly higher frequency of R mutations in CDRs than ex-
pected by chance (PCDR   0.05) is considered evidence for
positive, antigen-mediated selection of cells with the mu-
tated Ig. Conversely, a frequency of R mutations in FWRs
that is statistically lower than expected by chance (PFWR  
0.05) implies that there is pressure to maintain the struc-
tural integrity of Ig, possibly because antigen is providing
important growth/survival signals to the tumor cells (7).
As shown in Table III, two tumors had GL VL sequences
and the rest had 1–10 R mutations. CDR hypermutationSelective Transformation of Autoreactive gld B Cells 1472
was observed in 4 of 18 tumors and FWR conservation was
observed in 4 of 18 tumors. Tumors 142 and 425 exhibited
both VL CDR hypermutation and VL FWR preservation.
Notably, six VL sequences had R mutations in CDR1 and/
or CDR2 that gave rise to arginine (R) or asparagine (N)
residues important for DNA binding (3). Overall, 6 of 18
tumors had mutated CDR and/or conserved FWR in VL
sequences, suggesting that at least one third of the B cells
undergoing transformation were antigen selected. All six
tumors in this group were Ig isotype switched and those
producing antibodies (five out of six) were reactive with
nuclear antigens or RF. To test for evidence of ongoing
antigen-mediated selection, sequences from up to 15 clones
from each tumor were examined for intraclonal variation.
This was observed only in tumor 593 and at low fre-
quency. 2 of 15 clones had a single amino acid change at
the same position in VH CDR1 (not depicted).
PLs Exhibit a Gene Expression Profile Distinct from That of
Other B Cell Lineage Neoplasms. Recently, the opportunity
to understand the characteristics of different murine lym-
phoma types has been expanded through the use of gene
expression profiling (33). This work included lympho-
mas classified on histologic grounds as small B cell lym-
phoma (SBL), splenic marginal zone lymphoma (MZL),
Burkitt-like lymphoma (BLL), Burkitt lymphoma (BL),
follicular B cell lymphoma (FBL), and diffuse large B cell
lymphomas of centroblastic (CBL) or immunoblastic (IBL)
origin, as well as PCT cell lines. The results uncovered
class-specific expression signatures for SBL, BL, PCT, CBL,
and MZL, whereas the other types exhibited less distinctive
profiles (33).
To determine how PLs relate molecularly to these lym-
phoma types and to PCT, we compared their gene expres-
sion profiles using a 6,680 gene chip. We also studied a se-
ries of primary PC-related neoplasms from SJL- 2M / 
mice that have not been studied previously at the molecu-
lar level and whose place in the scheme of terminal B cell
differentiation is not known. These tumors resemble those
that arise in aging SJL mice, but they develop at an acceler-
ated rate (unpublished data).
PCA of the microarray data revealed that the PL tumors
were remarkably similar to each other in terms of gene ex-
pression. In the majority of cases, they also were readily
distinguished from lymphoma classes that originate from
cells that have not yet entered the terminal progression
program of PCs (Fig. 1). Further analyses of these data
identified 415 genes whose expression levels by t test dis-
tinguished PLs from BLLs, BLs, SBLs, CBLs, FBLs, MZLs,
and IBLs (Figs. S3 and S4). Most of these genes were ex-
pressed at significantly lower levels in the PL than the other
lymphoma types, consistent with the well-established down-
regulation of many genes that occurs as B cells mature to-
ward secretory stages of development. Fewer than 20 genes
Table III. Mutational Analysis of Tumor VL Sequences
Light chain variable region
FWR1, 2, and 3 CDR1 and 2
Tumor Ra Sb Pc Ra Sb Pc
BALB-gld
208 1 0 0.715 0 0 0.595
329 1 0 0.696 0 0 0.577
421 3 2 0.389 1 0 0.549
424 0 0 0.086 2 0 0.014
425 0 1 0.004 410.009
426 1 1 0.199 0 1 0.226
531 3 0 0.472 2 0 0.096
540 0 0 NAd 0 0 1.0
593 1 0 0.197 2 0 0.038
600 1 0 0.385 1 0 0.145
2685 1 4 0.004 3 1 0.154
3294 3 1 0.254 2 1 0.264
C3H-gld
142 1 1 0.016 410.010
205 7 6 0.032 3 2 0.401
217 1 0 0.206 1 1 0.238
221 0 0 NA 1 0 0.075
223 2 0 0.82 0 0 0.64
355 1 1 0.390 0 0 0.641
aNumber of R mutations.
bNumber of S mutations.
cP value was calculated according to Lossos et al. (reference 22). P val-
ues  0.05 are in bold.
dNA, not applicable.
Figure 1. PCA of lymphoma gene expression measured by oligonucle-
otide microarray. Expression levels of 6,680 genes were measured for
these 10 types of mouse lymphomas: BL, BLL, CBL, FBL, IBL, MZL,
PCT, SJL, SBL, and scid-passaged gld PL. Approximately 4,800 genes (no
missing value) were used for the analysis. PC1 and PC2 represent the
principal component 1 and principal component 2, respectively. Most
samples belonging to the same group are enclosed within a circle.Zhang et al. 1473
were selectively expressed at high levels in PL. One gene of
particular interest in this group was Apobec1, which encodes
an RNA editing protein that also may function as a DNA
mutator (34, 35).
Notably, the PL tumors also were distinct by PCA from
the PCT and primary SJL- 2M /  lymphomas (Fig. 1). To
further investigate the developmental relationships among
the PC-related neoplasms, we determined the genes that
best distinguish PLs from primary SJL- 2M /  tumors and
PCT cell lines using a t test. The expression patterns of the
99 genes identified in this manner showed that the SJL
neoplasms had features of both PCTs and PLs (Fig. 2). 13
genes were expressed at high to moderate levels in gld tu-
mors, at lower levels in the SJL tumors, and at very low
levels in PCTs. Among these were several genes—MHC
class II, Blk, Ccr7, and Icsbp—known to be down-regulated
as B cells mature to PCs (36, 37). This pattern of gene ex-
pression suggested that the SJL tumors were intermediate
in maturity between the PCTs and PLs.
Another set of 25 genes was expressed at higher levels in
PL than either the SJL or PCT series. These included
Casp2, another gene known to be down-regulated during
the maturation of B cells to PCs (37), and several genes that
were found to distinguish the gld tumors from all the non-
PC lymphomas examined—Mll,  Apobec1, and Mcrs1. Of
interest, four genes with established or suspected tumor
suppressor function were among the larger number of
genes expressed at lower levels in the PL–Zfp98 (38),
Tsg101 (39), Tssc4 (40), and Btg2 (41).
To further examine the developmental relationships among
the three sets of PC neoplasms, we interrogated a series of
30 genes modulated in expression late in B cell differentia-
Figure 2. Hierarchical clustering of gene expression data for 99 genes
that distinguish gld PLs from other PC neoplasms as determined by t test
at P   0.0000001. Only genes with high quality spots in each of the arrays
were evaluated. Genes of particular interest are listed on the right and dis-
cussed in Results. Tumor populations include PCT lines (PCT), primary
SJLs (SJL), and scid-passaged gld PLs (PL). PCT, SJL, and PL tumors are
identified by purple, blue, and yellow bars, respectively.
Figure 3. Changes in gene expression associated with PC differentia-
tion. (A) Hierarchical clustering of genes and arrays for 30 selected genes
altered in expression during late B cell differentiation. Gray spots indicate
missing or excluded data. (B) Quantitative PCR of eight selected genes.
Values represent mean   SEM for five separate samples normalized to a
value of 1 for BALB/c B cells. N, normal BALB/c splenic B cells; PL,
scid-passaged gld PL; SJL, primary SJL; PCT, PCT lines.Selective Transformation of Autoreactive gld B Cells 1474
tion (36, 37). The matrix generated by hierarchical cluster-
ing of both the genes and the arrays is shown in Fig. 3 A.
All PCTs but one fell on one branch of the tree generated
by the array samples, whereas PL and SJL neoplasms again
occupied the second branch. 13 of the 21 PL (61%) and 5
of the 10 SJL tumors were tightly grouped, with the re-
mainder being interspersed outside these immediate align-
ments. The genes also fell into several groups. In one major
group, 10 genes generally were expressed at the highest
levels by PL, at somewhat lower levels by many of the SJL
tumors, and at very low levels by the PCT. Among these
were the genes encoding CD45, CD22, CD19, CCR7,
ICSBP1, and FCGR2B (Fig. 3 A). A smaller group of
genes, including Irf4, Sdc1, and Xrcc5, were expressed at
highest levels in PCT and at similarly lower levels in PL
and SJL tumors (Fig. 3 A).
As an independent approach to comparing the matura-
tional state of these neoplasms and at the same time validat-
ing the array results, we used quantitative PCR to deter-
mine expression levels of eight genes that are differentially
expressed during differentiation to PCs (Fig. 3 B; refer-
ences 36 and 37). Relative to BALB/c splenic B cells, the
levels of Sdc1 (CD138), Xbp1, and Prdm1 (Blimp) were
generally found to increase from PL to SJL to PCT,
whereas those for Pax5, Bcl6, Cd19, Icsbp, and Cd86 de-
creased. These patterns of gene expression were consistent
with those seen on the microarrays. We conclude that lym-
phomas that develop in aging gld mice are readily distin-
guished from all the non-PC B cell lineage lymphomas
currently defined histologically and molecularly (33) and,
in the majority of cases, are less mature than pristane-
induced PCT and primary SJL- 2M /  PC neoplasms.
Primary and scid-passaged PLs Exhibit Similar Patterns of
Gene Expression. To ensure that the remarkably similar
gene expression profiles observed in the scid-passaged PLs
were not a reflection of tumor selection in the scid environ-
ment, we compared gene expression in scid-passaged
BALB-gld PLs, isolated primary BALB-gld PL cells, and
BALB/c splenic B cells by quantitative PCR. The genes
selected for this comparison were chosen from those that
distinguish the scid-passaged PLs from other B cell lineage
tumors and were either significantly increased (Fig. 4 A) or
decreased (Fig. 4 B) in expression relative to purified
BALB/c splenic B cells. Notably, these genes included can-
didates of potential importance in tumorigenesis (Apobec-1
[34, 35], Tssc4 [40], Btg2 [41], Bin1 [42], Prkcb [43], and
Mad1l1 [44]), lymphoma survival (BAFF [45–47] and IL-
10 [48, 49]), and autoimmunity (IL-10 [50, 51] and Ifi202/
203 [52]). Il6st, which encodes the gp130 component of
the IL-6 receptor (53), also was significantly decreased in
expression in primary and passaged tumors (Fig. 4 B). For
some genes, such as Apobec1, there were quantitative differ-
ences between levels expressed by primary and passaged tu-
mors, but in general, the distinguishing patterns of gene ex-
pression for PLs were in evidence before transplantation
(Fig. 4, A and B).
Discussion
The antibody specificities, characteristics of Ig genes, and
gene expression patterns presented here define the B cell
lineage lymphomas of Fasl-deficient mice as a novel subset
of PC neoplasms with an unusually restricted pattern of VH,
VL, DH, JH, and JL gene use and BCR specificities skewed
toward nuclear antigen and RF. Among 17 monoclonal Ig-
secreting PLs studied, 15 were autoreactive, with nuclear
antigen being the predominant specificity. 4 tumors were
reactive with both nuclear antigen and RF, and 6 of 12
BALB-gld PLs exhibited D–D fusions in VH CDR3. In ad-
dition, there was preferential use of JH4 and JK4/JK5 in the
tumor BCR. Gene expression profiling revealed that PLs
were readily distinguished from pre-GC or post-GC lym-
phomas of NFS.V  mice that have not reached the PC state
of differentiation and that they have many features in com-
mon with normal human and mouse B cells on their way
to becoming mature PCs (36, 37). A number of genes im-
plicated in tumorigenesis, B lymphoma growth, and au-
toimmunity were differentially expressed in both primary
and transplanted PLs.
The biased pattern of VH and VL gene use observed in
the PL is reminiscent of the distinctive repertoires of au-
toreactive B cells specific for nuclear antigen. Like the PL,
anti-dsDNA antibodies and ANA from MRL-lpr, MRL-
 / , (NZBxNZW)F1, and (SWRxNZW)F1  mice also
Figure 4. Primary and scid-passaged gld PLs have similar gene expres-
sion profiles. Quantitative PCR of selected genes expressed at signifi-
cantly higher levels (A) or significantly lower levels (B) in primary and
scid-passaged PLs relative to normal BALB/c B cells. Values represent
mean     SEM for four primary BALB-gld PLs and six scid-passaged
BALB-gld PLs normalized to a value of 1 for BALB/c splenic B cells. NB,
normal B cells; PT, primary tumor; SP, scid-passaged tumor.Zhang et al. 1475
disproportionately used the J558 and 7183 families and the
J558.18, J558.33, J558.40, J558.47, and J558.52 subfami-
lies (3, 5). These VH genes also tended to pair preferentially
with a restricted set of VL genes including members of the
V 8, V 2, V 4/5, V 9/10, V 21, and V 23 groups (3, 5).
These similarities and the autospecificities of the PL
strongly imply that they derive from the peripheral autore-
active B cell pool characteristic of lpr/gld mice.
D–D fusions and preferential use of downstream JH and
JL genes are common features of anti-DNA and antinucleo-
some antibodies in humans and mice with systemic lupus
erythematosus (3, 54–59). The preferential use of upstream
D genes and JH4 is suggestive of secondary D-JH rearrange-
ments (54, 55, 59), whereas preferential use of downstream
JL genes is indicative of secondary rearrangement of IgL loci
or receptor editing (56–58). The high proportion of PLs
using JH4 (55%) and the increased incidence of rearrange-
ment of VL to J 4 or J 5 strongly imply that the majority of
PLs derive from autoreactive B cells that have undergone
repeated D-JH and/or V-JL rearrangements. Secondary VH
rearrangements using D-JH4 also may occur in PLs by a
mechanism proposed previously by Klonowski and Mone-
stier (55) and Monestier and Zouali (59). Although chimeric
VH chains indicative of secondary rearrangement were not
observed in the PL, it is possible that they preferentially
used the embedded heptamer at the 3  end of FWR3 that
results in virtually seamless rearrangements (60–62).
Why predominantly Ig isotype–switched, autoreactive B
cells with the hallmarks of receptor revision appear to be se-
lectively targeted for transformation in gld mice is intriguing.
One explanation is that transformation occurs randomly in a
B cell population that is remarkably skewed toward recep-
tor-edited autoreactive B cells. Although hybridomas de-
rived from lpr splenic B cells are enriched for autoreactive
specificities (3–5), the actual representation of autoreactive B
cells within the unmanipulated B cell pool in tumor-free gld
mice is unknown. Another possible reason for selected trans-
formation of autoreactive B cells is that repeated activation
of Aid during somatic hypermutation or class switch recom-
bination increases the risk of transforming genetic mutations
(63, 64). BCR specificity also might be a factor in the trans-
formation process. Autoreactive B cells in lpr or gld mice in
all likelihood are chronically activated and have an extended
lifespan. These two factors are conducive to the accumula-
tion of transforming genetic defects and the clonal expansion
of mutated cells. Indeed, there is compelling evidence that
chronic stimulation of B cells by infectious agents such as
hepatitis C virus or Helicobacter pylori can culminate in lym-
phoma development (65–67). Notably, these lymphomas
often produce RF and other auto antibodies (11, 14, 17–19,
68). This might be explained by molecular mimicry or, al-
ternatively, RF-producing tumors may develop from RF B
cells driven to clonally expand by immune complexes (14,
17, 18, 67). With the caveat that the assignments of GL
genes may not be absolutely correct, the Ig VH and VL re-
gions of most PLs exhibited multiple nucleotide substitu-
tions in FWRs and CDRs. This observation, together with
Ig isotype switching in most tumors and a gene expression
profile consistent with early PC differentiation, strongly im-
plies that PLs derive from antigen-experienced B cells that
have encountered a GC-like environment. Somatic muta-
tion may occur in follicular GCs or extrafollicularly at the T
zone red pulp border as reported for RF B cells (69). ANA-
producing B cells and immune complex–binding RF B cells
might be particularly prone to chronic stimulation because
they can present multiple nucleosomal epitopes to T helper
cells and thereby generate polyclonal T cell help (70).
The relative importance of antigen drive in lymphoma-
genesis and lymphoma survival can be implied from analy-
sis of R and S mutations in the predicted amino acid se-
quences of IgH and IgL FWRs and CDRs (22). Using this
type of analysis on IgL genes, 33% of PLs showed evidence
of selection for FWR sequence conservation or diversifica-
tion of CDR sequence, suggesting selection by antigen.
The proportion of tumors with the hallmarks of antigen se-
lection increased to 61% if the R/S mutation analysis of Ig
VH genes also was included (not depicted). The lack of evi-
dence for intraclonal variation among individual PLs may
indicate a lack of pressure to enhance binding affinity, anti-
gen independence after transformation, or a tumor mi-
croenvironment not conducive to further mutation. Al-
though chronic stimulation by auto antigen might be an
etiologic factor in lymphomagenesis in gld mice, the im-
portance of continued antigen stimulation for proliferation
and survival of PLs is unclear. The reduced Ig expression
on PLs may preclude antigen-driven proliferation but still
facilitate the delivery of survival signals.
Earlier histologic and phenotypic analyses of PL tumors
propagated in immunodeficient mice indicated that the
majority of the tumors resembled activated B cells in phe-
notype and had a plasmacytoid morphology, although a
proportion of cells differentiated into typical PCs (2). This
phenotype suggested that most of the tumor cells were ar-
rested at an early stage in PC differentiation. Gene expres-
sion profiling and quantitative PCR established that the
PLs indeed are less differentiated than PCs or PCTs and
readily distinguishable from less mature B cell lineage tu-
mors. The similarities in gene expression patterns between
the scid-passaged PLs and primary PLs provides assurance
that the transplanted PLs are not undergoing appreciable
changes in gene expression as a result of selection or a
change from the gld to the scid microenvironment. Given
the rarity of murine immature PC tumors, the PLs will be
valuable tools for studying gene expression during PC dif-
ferentiation and possibly for developing diagnostic tran-
scriptional profiles.
Microarray analyses also led to the identification of genes
differentially expressed in PLs, including some that might
contribute to the transformation process. Genes that were
significantly up-regulated relative to BALB/c follicular B
cells included Apobec1, Prkcb, BAFF (Tnfst 13b), Ifi202, and
IL-10. Apobec1 is of particular interest because it was selec-
tively overexpressed in PLs and levels were particularly
high in primary tumors. APOBEC1, a cytidine deaminase
that constitutes the catalytic component of an RNA editing
complex, has homology to AID, an activation-induced cy-Selective Transformation of Autoreactive gld B Cells 1476
tidine deaminase required for somatic hypermutation, and
class switch recombination in B cells (34, 35). Constitutive
expression of Aid in transgenic mice leads to hypermuta-
tion of TCR and Myc genes and development of T cell
lymphomas (71). Although the function of APOBEC1 in B
cells is unknown, it may have oncogenic potential, as over-
expression in liver leads to hepatocellular carcinomas (72).
High expression of Prkcb, although not unique to PLs,
might be significant in view of the role of protein kinase C
  in survival signaling via NF- B and the finding that in-
hibitors of protein kinase C   induce cell death in lympho-
mas with dysregulated expression of the gene (73). Both
BAFF and IL-10 can be important autocrine growth and
survival factors for autoreactive B cells and B cell lineage
lymphomas (45–51). IL-10 also may protect lymphomas
from immune attack through its immunomodulatory ef-
fects on T cells and macrophages (50). Overexpression of
Ifi202 in PLs relative to normal BALB/c B cells warrants
further exploration considering the association of this gene
with susceptibility to systemic lupus erythematosus and the
survival of autoreactive B cells in NZB mice (52). Ifi202
expression might be regulated by IFN or IL-6 (74); how-
ever, the consistently low level of Il6st transcripts in PLs
suggests that Ifi202 regulation in PLs might be IL-6 inde-
pendent. In agreement with the down-regulation of IL6st,
IL-6 treatment of PL cell lines failed to induce phosphory-
lation of relevant JAKs or STATs (unpublished data). The
block in IL-6 signaling might be a factor in the arrest of PLs
at an early stage in PC development.
Genes of interest that were selectively down-regulated in
PLs and may have a role in tumorigenesis included Bin1,
Mad1l1, and Btg2. Although defective expression of these
genes has been described in a variety of nonlymphoid can-
cers, this is the first report of their down-regulation in B
lymphomas (41, 42, 44). Bin1, which was greatly reduced
in expression in both primary and transplanted PLs, en-
codes a Myc-interacting protein with tumor suppressor
properties (42, 75). BIN1 frequently is greatly reduced or
absent in malignant cells, and this deficit correlates with re-
sistance to cell death (42, 75). Defective stimulation of
Myc-induced apoptosis might be an important factor in
progression to malignancy in PLs.
In summary, we have demonstrated that the PLs that de-
velop spontaneously in gld mice derive predominantly from
antigen-driven autoreactive B cells, are arrested at an early
stage of PC differentiation, and exhibit a transcriptional
profile that distinguishes them from other murine B cell
neoplasms and also might be relevant to pathogenesis. This
model will be invaluable for further investigation of the re-
lationship between autoimmunity and B lymphomagenesis
and for elucidating changes in gene expression relevant to
early events in PC differentiation.
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